Member Info for Leapfroggy

We were told that we would gain endorsement of Axisbiotix, I presumed that this was as a product that contributed to psoriasis but it appears all we have gained is an endorsement that it will not make psoriasis worse! My semi-skimmed milk could probably achieve this. Did Axisbiotix actually fail to provide the proof that it could alleviate psoriasis symptoms? Hugely disappointing and part of ongoing smoke and mirrors by Ashman who led everyone to believe that we had an exceptionally close relationship with National psoriasis organisations

The multi nationals have the product for 14months!

I have sold a similar amount as I believe it will take £2m of Croda royalties this calendar year to get back to near 20p. I suspect sales to date have been disappointing as otherwise the product would be on sale by now. ITM and HUI offer a better likelihood of good returns.

Hope and hyperbole is their investment strategy. Whilst Elrico reckons a PE of 20 is currently reasonable!- to soon to say. If a few major retailers sell Zenakine by the end of the month I will stick around. There are companies I’m invested in like ITM, QED, Aurrigo and SRT that are all capable of generating new recurring sales of £5m which are very promising.

I definitely think that Madge from the local Women’s Institute could possibly, maybe, be putting Zenakine in her face cream and trialling it at the Summer Fare stall. As a VIP she has had a test sample for it for a year now and is ramping up production!

Only a third of companies have a PE of over 16% with the FTSE averaging 15%. What makes you confident about 20 at this point in time?

Take out Elrico and our pair of (filtered)’ Rampers in Chief ‘ there’s not much going on with this board.

Whilst it could, the company has failed to develop/launch products in a timely manner. It has very weak Board and managerial expertise in marketing/product development and appears to be top heavy in the finance function. I would suggest that Zenakine income needs to be at least £4m p.a. to justify the current SP. Let’s hope we see some retail sales from leading companies and that competitors don’t launch competing products. Boots already has its Future Renew products developed by no other than our friends at Manchester University! What is clear is that Croda are marketing Zenakine strongly but £50m of sales may be some time off given zero retail sales to date.

What is most interesting from this is that Zenakine has been proven to provide synergy for existing products/formulations boosting the efficacy of the existing product. This opens up a whole new market as it allows companies to sell their customer a new second generation product. With Zenakine 1+1 can equal 3!

Great news, the 24700 buy is mine!

I sold two thirds of my shares at a very good profit, I feel that this is oversold given the prospects. The 30,000 buy is mine.

It does ‘seem’ to be something that Croda is pushing hard. However it shouldn’t have to be up to investors to scramble around to provide this evidence. At the very least we should have something to indicate that the launch has been successful even if it’s only a ‘Croda agreed’ quote. Yes we have an NDA but that surely does not mean all information is embargoed and why on earth is the NDA in place as I would have thought any future references to Zanakine in SBTX RNS’s would be agreed by Croda anyway.

Good luck on that. I remember when he said he had an incredibly close relationship with the Psoriasis Association and indicated we were pushing against an open door, then said sales were increasing at an alarming rate which turned out to be a few boxes a month and if I remember rightly had to dump out of date stock. I wonder if he is delusional!

Twice now Ashman has said that he will answer additional questions submitted to the Investor Meet and twice he has not kept his word. Seems to be reflective of a wider malaise of him not being able to deliver/disdain for shafeholders.

And weren’t we told that last year would be transformative? Maybe not going down the pan counts as transformative.

Good luck to you and all holders

And set yourself an amount you are willing to lose and sell at that point. I advised a friend to buy into RKH but sell when it fell by 15%. I got out then but he said share prices go up and down and is still holding having lost 90% of his money

Best to understand that you have bought a highly speculative share in a company that will have to dilute at a substantial discount to advance its mining interests. This board is mainly made up of rampers that will post constantly in the hope they can keep the price up so consider what is the value of the company and how does a company with no income keep the lights on? I invested like you a month ago and sold out today and came out evens. Most people are quick to buy in and slow to sell in a falling market.

Blinked and MET1 and it’s up another 9%. AIM madness for a company with no revenue!

Yes it rose to 75p and I reckoned at that time it was worth 25p on a good day but I sold all my other shares and made a good profit but then sold everything quickly as it started to fall. Aim is all about momentum not necessarily value and most people do not sell into the fall quickly enough. After all why not wait and buy back in when it falls, in my case at 7p. Like many people I respect I started selling down after the launch. Bought into MET1 which is probably not worth 30p let alone 45p so my finger is ready on the sell button